AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
2
Former Mossad chief and real estate tycoons back controversial Israeli drone company
3
Israel’s war with Iran costs up to $550 million a day
4
Israel orders airborne laser system for fighter jets and helicopters
5
Jensen Huang: Nvidia “100% in Israel” despite war
More news

Pharmaceuticals

20 stories about Pharmaceuticals
ריצרד פרנסיס נשיא ו מנכל טבע

Teva secures $400 million from Blackstone to advance flagship IBD drug

04.03.26|Sophie Shulman
The funding bolsters late-stage development of Duvakitug as the company races toward a $30 billion market.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva’s 2026 forecast disappoints despite strong finish to 2025

28.01.26|Sophie Shulman
Lower revenue guidance overshadows rapid growth in branded drugs.
המרכז הלוגיסטי של חברת טבע בשוהם

Teva bets on vitiligo drug in deal worth up to $500 million

12.01.26|Sophie Shulman
Agreement with Royalty Pharma underscores shift toward branded medicines.
המטה הגלובלי של חברת טבע בת"א

Teva’s branded drugs spark investor optimism

06.11.25|Sophie Shulman
The pharmaceutical company recorded its 11th consecutive quarter of growth, with revenue of $4.5 billion, thanks to sales of its brand-name drugs Austedo, Ajovy and Uzedy, which jumped 33%.
ריצ'רד פרנסיס מפגש העיתונאים

Teva shares soar on strong third-quarter performance

05.11.25|Sophie Shulman
Revenue climbs 3% to $4.5 billion, exceeding analysts’ expectations.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva returns to profit in Q2 but misses on revenue

30.07.25|Sophie Shulman
Austedo disappoints, while Uzedy and Ajovy drive upside in brand-name drugs.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s quiet layoff announcement reveals bold restructuring plan

08.05.25|Sophie Shulman
CEO signals this is ‘just the first step’ in multi-year effort to streamline and scale.
מנכ"ל טבע ריצ'רד פרנסיס מפגש עיתונאים 2025

Teva to cut 3,000 jobs by 2027 in drive toward higher profit margins

07.05.25|Sophie Shulman
Pharma giant targets 30% operating margin by laying off approximately 8% of its global workforce as it boosts forecasts on drug sales and updates its "Pivot to Growth" strategy. 
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva signals return to fundraising after decade-long crisis

08.02.25|Sophie Shulman
Israeli pharmaceutical giant eyes stock offering as part of its recovery plan.
מגזין מנהלים ריצ'רד פרנסיס מנכ"ל טבע

Teva’s stock surge comes to a halt, falling 14% amid weak 2025 outlook

30.01.25|Sophie Shulman
Despite a strong 80% gain in 2024, Teva’s stock dropped after the company revealed disappointing profitability and cash flow forecasts.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva’s 10-year turnaround takes shape with stunning trial results

18.12.24|Sophie Shulman
Duvakitug signals a brighter future for the Israeli pharma giant. 
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva shares jump as its most promising drug shows exceptional trial results

17.12.24|Sophie Shulman
Duvakitug, designed to treat colitis and Crohn’s disease, exceeded expectations and positions Teva to compete in the $28 billion global market for inflammatory bowel disease treatments.
לוגו חברת טבע ב מטה החברה ב תל אביב 20.2.24

Teva's vision 2025: Building on momentum for future market leadership

04.08.24|Sophie Shulman
Richard Francis’ strategic plan aims to transform Teva into a powerhouse of growth and innovation.
ריצ'רד פרנסיס נשיא ו מנכ"ל חברת טבע

Teva posts impressive Q2 results, ups 2024 revenue forecast

31.07.24|Sophie Shulman
Strong sales of Austedo and Ajovy lead to double-digit growth for the Israeli pharma company.
האקר האקרים סייבר

Cyber attack shuts down Israeli pharma company's distribution

17.06.24|Omer Kabir
Rekah, a prominent local producer of medicines, cosmetics, vitamins, and nutritional supplements, said it is working "to contain the incident, locate and thwart it, and restore compromised systems to operation"
ריצ'רד פרנסיס מנכ"ל טבע

Teva shares continue to surge, climb to highest mark in more than five years on Q1 results

08.05.24|Sophie Shulman
AUSTEDO continues to be Teva's main growth engine and its flagship drug, with annual growth of 67% in sales
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Why are Teva shares surging and how does it plan to keep it up

04.04.24|Uri Tel Tenne
Since the beginning of the year, Teva's shares have risen by about 36%, and are among the best performing stocks on the Tel Aviv Stock Exchange. Why is this happening and how is the company's CEO planning to build on the momentum?
מוסף שבועי 22.2.24 היזמית מיכל צור

"Until there is unity and equality here, Israel has no chance"

22.02.24|Sophie Shulman
At night, serial entrepreneur Michal Tsur doesn’t sleep, worrying about her son fighting in the army. During the day, she is busy with her third startup, Remepy, and dreaming of a new country - the same country for which she took to the streets as one of the leaders of last year’s protest against the judicial reform
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory
More Articles